Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Pegasys user fee goal

This article was originally published in Pharmaceutical Approvals Monthly

  • News

Executive Summary

Roche is granted priority review status for its combination therapy of Pegasys (peginterferon alfa-2a) and ribavirin, establishing a user fee goal of December 2002. The firm submitted the BLA in June for treatment of chronic hepatitis C in patients without cirrhosis and patients with cirrhosis with compensated liver disease (Pharmaceutical Approvals Monthly, June 2002, p. 3

Roche is granted priority review status for its combination therapy of Pegasys (peginterferon alfa-2a) and ribavirin, establishing a user fee goal of December 2002. The firm submitted the BLA in June for treatment of chronic hepatitis C in patients without cirrhosis and patients with cirrhosis with compensated liver disease (Pharmaceutical Approvals Monthly, June 2002, p. 3)
Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The Aspirin Test For AI?

Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire

Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says

See All
UsernamePublicRestriction

Register

PS001997

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By